Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
10:30 ET | 343 | 3.62 |
11:38 ET | 100 | 3.645 |
11:45 ET | 100 | 3.65 |
12:00 ET | 100 | 3.67 |
12:14 ET | 100 | 3.65 |
12:20 ET | 100 | 3.65 |
12:54 ET | 100 | 3.6 |
01:24 ET | 899 | 3.58 |
01:30 ET | 100 | 3.56 |
02:09 ET | 200 | 3.59 |
02:13 ET | 100 | 3.58 |
02:36 ET | 505 | 3.59 |
02:49 ET | 100 | 3.6 |
03:02 ET | 300 | 3.62 |
03:14 ET | 100 | 3.61 |
03:38 ET | 100 | 3.6 |
03:39 ET | 100 | 3.61 |
03:56 ET | 200 | 3.61 |
03:59 ET | 3205 | 3.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 198.8M | -1.9x | --- |
Aldeyra Therapeutics Inc | 190.1M | -6.3x | --- |
Rani Therapeutics Holdings Inc | 189.6M | -2.9x | --- |
Acrivon Therapeutics Inc | 189.6M | -2.5x | --- |
Skye Bioscience Inc | 209.4M | -1.2x | --- |
Trevi Therapeutics Inc | 188.1M | -7.6x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $198.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-1.88 |
Book Value | $5.64 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.